ENTA - Enanta Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$48.20
DETAILS
HIGH:
$87.00
LOW:
$20.00
MEDIAN:
$54.00
CONSENSUS:
$48.20
UPSIDE:
245.52%
About Enanta Pharmaceuticals, Inc. (https://www.enanta.com)
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Scott T. Rottinghaus | Chief Medical Officer | 1974 | $863,706 USD |
| Yat Sun Or | Chief Scientific Officer | 1952 | $814,285 USD |
| Jay R. Luly | President, Chief Executive Officer & Director | 1956 | $742,273 USD |
| Nathaniel S. Gardiner | Consultant | 1954 | $672,675 USD |
| Brendan Luu | Chief Business Officer | 1975 | $622,856 USD |
| Matthew Kowalsky | Chief Legal Officer & Corporate Secretary | 1973 | $575,652 USD |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 1978 | $496,852 USD |
| Harry R. Trout | VP of Finance & Interim Principal Financial Officer | 1969 | – |
| Jennifer Viera | Executive Director of Investor Relations & Corporate Communications | – | – |
| Kathleen S. Capps | Executive Director of Accounting, Controller & Interim Principal Accounting Officer | 1985 | – |